A Drug Slows A.L.S. For the First Time, Some Symptoms Reverse. Science Keeps Its Promises, Slowly.

What Happened

Tofersen, a drug developed by Biogen, has shown the ability to reverse some symptoms of A.L.S. (amyotrophic lateral sclerosis) in certain patients — a disease that has been almost universally progressive and fatal since it was first described. The treatment targets a genetic mutation (SOD1) responsible for a subset of A.L.S. cases. This marks one of the first times any A.L.S. treatment has demonstrated reversal, rather than merely slowing, of neurological decline.

Historical Context

A.L.S. has resisted treatment for over 150 years since Jean-Martin Charcot first described it in 1869. Only two drugs — riluzole (1995) and edaravone (2017) — had ever been approved, and both offered only modest slowing of progression. Tofersen received FDA accelerated approval in 2023. The SOD1 mutation it targets accounts for roughly 2% of all A.L.S. cases (~5,000 new U.S. diagnoses per year), meaning the immediate beneficiary pool is small — but the antisense oligonucleotide mechanism it uses is a platform technology with broader potential. Historically, breakthroughs in rare disease subsets often open doors for wider populations: the first targeted cancer therapies worked on narrow genetic subgroups before expanding.

What's In Your Control

Whether you share this news with someone living with A.L.S. or caring for a patient — it may matter enormously to them. Whether you follow the broader pipeline of antisense oligonucleotide treatments if this area is personally relevant. Whether you allow yourself a moment of genuine optimism: not all scientific news is spin.

Does This Require Action?

For the vast majority of readers: awareness only, and perhaps quiet gratitude that science moves forward. For those with a family history of SOD1-linked A.L.S.: speaking with a neurologist about genetic testing and trial eligibility is worth doing now.